P/B
8,8
Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
$16.2B
Market Cap • 10/27/2026
1994
(32 years)
Founded
2000
(26 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
6,6
P/EBITDA
16,2
P/OCF
13,7
P/FCF
13,8
P/E
20,5
BVPS
7,4
EPS
3,2
Market Cap
Market Cap
16,2B
EV
15,5B
EV/Revenue
6,4
EV/EBITDA
15,5
EV/EBIT
16
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
7,2%
Total Yield
7,2%
Payout
0%
Retained Earnings
-262,5M
Profitability
Gross Margin
96,5%
EBITDA Margin
41%
EBIT Margin
39,9%
Net Margin
35,3%
D&A/EBITDA
0%
R&D/Revenue
33,8%
Capex/Revenue
0,5%
Capex/D&A
38,7%
Capex/OCF
0,9%
SBC/OCF
9,5%
% PPE
13,7%
% Goodwill
2,6%
ROE
44,4%
ROIC
56,8%
Growth
CAGR Revenue 5Y
16,1%
CAGR Op. Income 5Y
57,5%
CAGR Net Income 5Y
55,7%
CAGR EPS 5Y
61,2%
CAGR OCF 5Y
34,2%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,5
Quick Ratio
3,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!